Skip to main content

Sinha Vikas's Form 4/A amendment

Amended

Verona Pharma plcVRNA · filed May 22, 2025

Accession no.
0001104659-25-051979
Filed
May 22, 2025
Trade date
Apr 29, 2025
Filing delay
23 days
Rule 10b5-1 plan
Checked
Original filed
May 1, 2025

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.43M. It was filed 23 days after the trade.

This amendment replaces 0001104659-25-043644 (filed May 1, 2025).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sinha VikasCIK 0001337845Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 29, 2025Ordinary SharesMOption exerciseAcquired+120,384$1.70+$204,652.8194,824Direct
Apr 29, 2025Ordinary SharesSSaleDisposed−120,384$8.92−$1,073,825.2874,440Direct
Apr 29, 2025Ordinary SharesMOption exerciseAcquired+39,616$0.50+$19,808114,056Direct
Apr 29, 2025Ordinary SharesSSaleDisposed−39,616$8.92−$353,374.7274,440Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 29, 2025Ordinary SharesMOption exerciseDisposed−120,384$0.00$00Direct
Apr 29, 2025Ordinary SharesMOption exerciseDisposed−39,616$0.00$0160,384Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F2

Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F3

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.

F4

Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.

F5

The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F6

The option is fully vested.

Read the full filing on SEC EDGAR (opens in a new tab)